Staging preview: health content pending qualified review
D2C Peptides

Reconstitution and storage

How to reconstitute CJC-1295 with DAC

Reconstituting CJC-1295 with DAC means dissolving its freeze-dried powder in a measured volume of liquid for lab use. No official method exists, because no form of CJC-1295 is part of an approved drug or has a USP monograph.1 FDA, citing a supplier source, reports a water solubility of about 2 mg per mL.2

This page summarizes published sources for information only. It is not medical advice and does not tell anyone to use a product. Questions about your own health belong with a licensed clinician. For questions about an order or a product, contact us.

Before you start

CJC-1295 with DAC has no label, so no official diluent, volume or use-by time exists.1 The handling figures published for it come from FDA's 2024 review, which cites supplier sources for most of them.32 This page covers lab handling: what is in the vial, the supplies, the concentration math and storage. It does not give instructions for injecting CJC-1295.

What is in the vial

The vial is listed as 2 mg of dry powder; the diluent is listed separately. FDA describes CJC-1295 DAC free base as a fine white lyophilized (freeze-dried) powder.3 The listing does not say whether the powder is the free base or a salt. FDA evaluated the DAC free base, DAC acetate and DAC trifluoroacetate (TFA) as separate bulk substances, and its formula for the acetate adds acetate units to the peptide.12 The vial and its listed supplies are on the CJC-1295 with DAC for sale page.

Supplies

Five supplies are listed with this vial:

The steps every freeze-dried vial shares are explained in How to reconstitute a peptide vial.

Lab steps

  1. Check the lot. If a certificate of analysis for the vial's lot is posted on the lab results page, check that its reported mass fits the DAC form (see the math below).
  2. Pick a concentration. Choose a volume from the table below or with the reconstitution calculator. Keeping the solution at or under about 2 mg per mL, the solubility FDA reports from a supplier source, means at least 1 mL for a 2 mg vial.2
  3. Keep it sterile. The bacteriostatic water label calls for aseptic technique for every entry into and withdrawal from a container.17 Swab each rubber stopper before the needle goes in.
  4. Add the diluent slowly. Let the liquid run down the inside wall of the vial instead of jetting it onto the powder; labels of approved freeze-dried products give this step to avoid foaming.1516
  5. Dissolve without shaking. Swirl or roll the vial gently until no powder remains; those labels say not to shake.1516 FDA notes that peptides like CJC-1295 can be very sensitive to conditions such as pH, heat and concentration, which can make them clump (aggregate) and break down.5
  6. Inspect the solution. Check that it is clear and free of particles, and note any cloudiness in the lab record.17 FDA links aggregation in peptides like CJC-1295 to loss of activity and to a higher risk of immune reactions.56
  7. Split it up. The supplier source in FDA's review recommends dividing the dissolved peptide into several vials so that no portion is frozen and thawed repeatedly.3 Approved products differ: the EGRIFTA SV label says not to freeze or refrigerate its mixed solution.15
  8. Label each vial. Write the compound, lot, concentration, diluent and date on it.

Concentration math

Divide the milligrams in the vial by the milliliters of diluent added: the result is the concentration in mg per mL. To find the volume that holds a given amount, divide that amount by the concentration.

Diluent added to 2 mg Concentration Micrograms in 0.1 mL Molar concentration, DAC free base
1 mL 2 mg/mL 200 about 548 µM
1.5 mL 1.33 mg/mL 133 about 366 µM
2 mL 1 mg/mL 100 about 274 µM
2.5 mL 0.8 mg/mL 80 about 219 µM
3 mL 0.67 mg/mL 67 about 183 µM

Volumes under 1 mL would take 2 mg past the reported solubility of about 2 mg per mL.2 The molar column uses PubChem's molar mass of 3647.2 g/mol: 0.002 g ÷ 3647.2 g/mol is about 548 nanomoles of peptide.4

Worked example. Adding 2 mL gives 2 ÷ 2 = 1 mg per mL, about 274 µM. To make 1 mL of a 10 µM working solution for a cell assay, use C1 × V1 = C2 × V2: take 10 × 1 ÷ 274 = 0.036 mL (about 36 µL) of stock and add 0.964 mL of diluent.

Two things can shift these numbers:

  • Salt form. If the 2 mg was weighed as an acetate or TFA salt, part of that weight is the counterion, so the peptide content and every molar value are lower. FDA's acetate formula does not fix how many acetate units are present, so the size of the correction depends on the lot's certificate.2
  • A different molecule. A certificate showing 3367.95 g/mol points to CJC-1295 without DAC, which FDA treats as a different substance.51 The same 2 mg of it would be about 594 nanomoles, and FDA says findings for the DAC form cannot be applied to it.14

The peptide calculator handles other vial sizes, and the units converter turns milliliters into insulin-syringe units. These are lab calculations, not amounts for a person.

Storage before and after mixing

Form Condition What the source reports
Powder, DAC free base -20 °C The storage temperature in FDA's review, citing supplier sources3
Powder, DAC free base Below -20 °C Expected to be stable, per FDA2
Dissolved 4 °C Can be kept at this temperature, per FDA citing supplier sources3
Dissolved, to be frozen Several separate vials Splitting avoids repeated freezing and thawing3

No stability study of dissolved CJC-1295 with DAC was found in the sources for this page, so there is no tested use-by time after mixing. FDA's general advice for multi-dose vials of sterile medicine is to discard them 28 days after first use, a rule for medicine vials rather than a measured figure for this peptide.7 The peptide storage guide covers storage practice in general.

CJC-1295 injection site: what studies report

Studies that name a route gave CJC-1295 with DAC under the skin (subcutaneously), but the sources reviewed here do not record where on the body.89 Injection-site reactions such as irritation, redness, hardening, pain or itching were the most common side effect: about 70% of people had one after a single dose, and every participant given repeated doses had one.1011 In FDA's review of animal studies, repeated daily injections under the skin caused bleeding, inflammation and tissue death at the injection site in rats and dogs.12 FDA also says compounded CJC-1295 may pose a risk of immune reactions for certain routes of administration.13

This site gives no injection directions for CJC-1295, which is not an FDA-approved drug.1

Start from What is CJC-1295 with DAC? for the overview. Research doses are on CJC-1295 with DAC dosage, the reactions reported in trials on CJC-1295 with DAC side effects, and the evidence for each claimed use on CJC-1295 with DAC benefits and uses.

More on CJC-1295 with DAC

  • CJC-1295 with DAC side effects

    Side effects of CJC-1295 with DAC as reported in clinical trials and published studies, with links to the full profile. Reviewed by a qualified reviewer.

  • CJC-1295 with DAC dosage

    Published dosing information for CJC-1295 with DAC from clinical trials and published studies, with its source, and why it is not advice for you.

  • CJC-1295 with DAC benefits and uses

    What published sources report about CJC-1295 with DAC and its uses, with the evidence level of each finding. No promises.

CJC-1295 with DAC in the store

CJC-1295 with DAC for sale: strengths, stock and shipping are on the product page.

For research use only. Not for human or veterinary use. Read the research use policy.

Frequently asked questions

How much bacteriostatic water is used for a 2 mg vial of CJC-1295 with DAC?

No official volume exists, because CJC-1295 has no approved label or USP monograph.1 The volume simply sets the concentration: 1 mL gives 2 mg per mL, 2 mL gives 1 mg per mL and 3 mL gives about 0.67 mg per mL. FDA reports a water solubility of about 2 mg per mL from a supplier source, so 1 mL is the smallest volume that stays within that figure.2 The reconstitution calculator works out any other volume.

How long does CJC-1295 with DAC last after mixing?

No tested figure exists. FDA's 2024 review, citing supplier sources, says the dissolved peptide can be kept at 4 °C and recommends splitting it into several vials to avoid repeated freezing and thawing, but it gives no time limit.3 For multi-dose vials of sterile medicine in general, FDA recommends discarding the vial 28 days after first use.7 That is a rule for medicine vials, not a stability result for CJC-1295, so label each vial with its mixing date.

Where is CJC-1295 injected in studies?

Published human studies that report a route gave CJC-1295 with DAC by injection under the skin, but the sources reviewed do not say where on the body.89 Injection-site reactions were its most common side effect, affecting about 70% of people after one dose.10 In rats and dogs, repeated daily injections under the skin caused bleeding, inflammation and tissue death at the injection site.12 FDA calls its long-term safety in people unknown, and this site gives no injection directions for it.11

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of December 4, 2024: FDA Evaluation of CJC-1295-related bulk drug substances (PDF page 7, Introduction). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  2. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 19, CJC-1295 DAC properties and conclusions). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  3. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 17, CJC-1295 DAC stability). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  4. PubChem compound record CID 91971820 (Cjc 1295). PubChem, National Library of Medicine (NIH), 2026.
  5. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 12, CJC-1295 free base chemistry and peptide stability). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  6. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 43, immunogenicity). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  7. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. US Food and Drug Administration, 2026.
  8. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (Teichman SL et al.), PubMed PMID 16352683. Journal of Clinical Endocrinology and Metabolism (abstract via NCBI PubMed E-utilities), 2006.
  9. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 39, Ionescu and Frohman 2006 details). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  10. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 41, adverse events in Teichman 2006). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  11. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 46, human safety conclusions). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  12. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 36, nonclinical toxicology conclusions). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  13. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). U.S. Food and Drug Administration, 2026.
  14. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 31, DAC caveats and pharmacokinetics). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  15. EGRIFTA SV (tesamorelin for injection) prescribing information and instructions for use. U.S. Food and Drug Administration (Drugs@FDA label), 2024.
  16. ZOMACTON (somatropin) for injection, prescribing information (revised 7/2025). DailyMed, U.S. National Library of Medicine, 2025.
  17. Bacteriostatic Water for Injection, USP (multiple-dose vial) prescribing information. Hospira, Inc. (Pfizer labeling), 2019.